From AKI dosing to CKM therapeutic inertia, experts at ASN Kidney Week 2026 pointed to pharmacists as key to moving new kidney data into practice.
|Articles|January 22, 2018
What Should Specialty Pharmacists Know About the ReDOS Clinical Trial?
Tanios Bekaii-Saab, MD, FACP, Mayo Clinic Cancer Center, talks about key takeaways from the phase 2 ReDOS clinical trial for specialty pharmacists.
Advertisement
Advertisement
Related to this article
In pooled CORALreef data, patients with eGFR below 60 had a 65.9% placebo-adjusted LDL-C reduction at week 24, with safety comparable to placebo.
CDC surveillance data show that approximately 10% of adults hospitalized with RSV died during hospitalization or within 60 days of discharge.
VAX-31 met all primary immunogenicity end points against PCV20 and PCV21 in the pivotal OPUS-1 trial.
ESMO 2026 lung cancer trials reshape first-line care with tarlatamab maintenance, stronger KRAS G12C results, and TROP2 ADC gains, raising pharmacy monitoring demands.
ESMO 2026 breast cancer updates show ribociclib boosts survival, while immunotherapy and extended endocrine therapy improve end points without longer overall survival.
Expert Q&A: Geisinger Investigator Discusses Low Flu Vaccination Rates, ICU Findings in Older Adults
A study author explains how pharmacists can help close vaccination gaps in rural communities and what lower ICU admission rates among vaccinated older adults may mean.
Every-12-week immune checkpoint inhibitor dosing failed to establish noninferiority in the phase 3 MOIO trial, with an overall survival imbalance and no meaningful safety advantage over standard treatment.
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Happens Before the First Dose? 5 Steps That Shape Lung Cancer Treatment
2
October 2026 in Pain Management: 4 Updates on Treatment and Pharmacy Practice
3
Nicotine Vaping Linked to Lower Vascular Function in Young Adults
4
Full IDWeek Data Highlights 31-Valent Pneumococcal Conjugate Vaccine Candidate in Adults
5